Bacteriophage for the treatment of bacterial biofilms
AssigneeBiocontrol Limited
InventorsGavin Hughes, James Taggart Walker, Richard Sharp, Anthony Hart
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition for treating a bacterial biofilm, comprising a first bacteriophage that is capable of infecting a bacterium within said biofilm, and a first polysaccharide lyase enzyme that is capable of degrading a polysaccharide within said biofilm. The composition preferably further comprises a pharmaceutically-acceptable antimicrobial agent, and may also include a DNase. Also provided are modified bacteriophages, methods of creating modified bacteriophages, use of said compositions and bacteriophage for treating biofilms, and methods for treating biofilms using the bacteriophages and compositions of the invention.
Claims40
A composition for treating a bacterial biofilm wherein the biofilm is a biofilm of a patient, said composition comprising a first bacteriophage that is capable of infecting a bacterium within said biofilm, a first polysaccharide lyase enzyme that is capable of degrading a polysaccharide within said biofilm, and a pharmaceutically-acceptable antimicrobial agent,
- wherein the biofilm includes a Pseudomonas sp.,
- the first bacteriophage is capable of infecting said Pseudomonas sp., and the first bacteriophage is selected from the group consisting of GH4 (ECACC Accession No. 02121203), GH6 (ECACC Accession No. 02121202), GH13 (ECACC Accession No. 02121201), GH14 (ECACC Accession No. 02121204);
- and a bacteriophage having accession No. ATCC 12055-B1, ATCC 12055-B2, ATCC 12055-B3, ATCC 14205-B1, ATCC 14206-B1, ATCC 14207-B1, ATCC 14209-B1, ATCC 14210-B1, ATCC 14211-B1, ATCC 14212-B1, ATCC 14213-B1, ATCC 14214-81, ATCC 15692-B2, ATCC 15692-B3, ATCC 25102-B1, ATCC BAA-26-B1, ATCC BAA-27-B1, ATCC BAA-28-B1, ATCC BAA-28-B2, ATCC BAA-29-B1, ATCC BAA-30-B1, ATCC BAA-31-B1, ATCC BAA-47-B1, ATCC BAA-79-B1, ATCC BAA-81-B1, and ATCC BAA-81-B2.
A method of treating a biofilm infection, wherein the biofilm is a biofilm of a patient, comprising administering to a patient:
- a first bacteriophage capable of infecting a bacterium within said biofilm;
- a first polysaccharide lyase enzyme capable of degrading a polysaccharide within said biofilm;
- and
- a pharmaceutically-acceptable antimicrobial agent,
- wherein the biofilm includes a Pseudomonas sp.,
- the first bacteriophage is capable of infecting said Pseudomonas sp., and the first bacteriophage is selected from the group consisting of GH4 (ECACC Accession No. 02121203). GH6 (ECACC Accession No. 02121202), GH13 (ECACC Accession No. 02121201), GH14 (ECACC Accession No. 02121204);
- and a bacteriophage having accession No. ATCC 12055-B1, ATCC 12055-B2, ATCC 12055-B3, ATCC 14205-B1, ATCC 14206-B1, ATCC 14207-B1, ATCC 14209-B1, ATCC 14210-B1, ATCC 14211-B1, ATCC 14212-B1, ATCC 14213-B1, ATCC 14214-81, ATCC 15692-B2, ATCC 15692-B3, ATCC 25102-B1, ATCC BAA-26-B1, ATCC BAA-27-B1, ATCC BAA-28-B1, ATCC BAA-28-B2, ATCC BAA-29-B1, ATCC BAA-30-B1, ATCC BAA-31-B1, ATCC BAA-47-B1, ATCC BAA-79-B1, ATCC BAA-81-B1, and ATCC BAA-81-B2.
Dependencies are inferred from the claim text.